Alba Clara Sarti

Dr. Alba Clara Sarti

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
VVValentina Vultaggio-Poma
Valentina Vultaggio-Poma
ASAlba Clara Sarti
Alba Clara Sarti
Francesco Di VirgilioFrancesco Di Virgilio
Francesco Di Virgilio
Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor microenvironment (TME), where it can promote tumor progression or tumor suppression depending on its concentration and on the specific ecto-nucleotidases and receptors expressed by immune and cancer cells. ATP can be released from cells via both specific and nonspecific pathways. A non-regulated release occurs from dying and damaged cells, whereas active release involves exocytotic granules, plasma membrane-derived microvesicles, specific ATP-binding cassette (ABC) transporters and membrane channels (connexin hemichannels, pannexin 1 (PANX1), calcium homeostasis modulator 1 (CALHM1), volume-regulated anion channels (VRACs) and maxi-anion channels (MACs)). Extracellular ATP acts at P2 purinergic receptors, among which P2X7R is a key mediator of the final ATP-dependent biological effects. Over the years, P2 receptor- or ecto-nucleotidase-targeting for cancer therapy has been proposed and actively investigated, while comparatively fewer studies have explored the suitability of TME ATP as a target. In this review, we briefly summarize the available evidence suggesting that TME ATP has a central role in determining tumor fate and is, therefore, a suitable target for cancer therapy.

22 May 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
Francesco Di VirgilioFrancesco Di Virgilio
Francesco Di Virgilio
YTYong Tang
Yong Tang
ASAlba Clara Sarti
Alba Clara Sarti
MRMarco Rossato
Marco Rossato

5 April 2021 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
ASAlba Clara Sarti
Alba Clara Sarti
VVValentina Vultaggio-Poma
Valentina Vultaggio-Poma
Francesco Di VirgilioFrancesco Di Virgilio
Francesco Di Virgilio

18 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAlba Clara Sarti
Alba Clara Sarti
VVValentina Vultaggio-Poma
Valentina Vultaggio-Poma
SFSimonetta Falzoni
Simonetta Falzoni
SMSonia Missiroli
Sonia Missiroli
Anna Lisa GiulianiAnna Lisa Giuliani
Anna Lisa Giuliani
Francesco Di VirgilioFrancesco Di Virgilio
Francesco Di Virgilio
Basal expression of the P2X7 receptor (P2X7R) improves mitochondrial metabolism, ATP synthesis and overall fitness of immune and non-immune cells. We investigated P2X7R contribution to energy metabolism and subcellular localization in fibroblasts (mouse embryo fibroblasts and HEK293 human fibroblasts), mouse microglia (primary brain microglia and the N13 microglia cell line), and heart tissue. The P2X7R localizes to mitochondria, and its lack a) decreases basal respiratory rate, ATP-coupled respiration, maximal uncoupled respiration, resting mitochondrial potential, mitochondrial matrix Ca 2+ level, b) modifies expression pattern of oxidative phosphorylation (OxPhos) enzymes, and c) severely affects cardiac performance. Hearts from P2rx7 -deleted versus WT mice are larger, heart mitochondria smaller, and stroke volume (SV), ejection fraction (EF), fractional shortening (FS) and cardiac output (CO), are significantly decreased. Accordingly, physical fitness of P2X7R-null mice is severely reduced. Thus, the P2X7R is a key modulator of mitochondrial energy metabolism and a determinant of physical fitness.